Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS
NCT01417767
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Myelodysplastic Syndromes
Interventions
DRUG:
CHG regimen
DRUG:
5-aza-deoxycytidine
Sponsor
Xiao Li